Edmp Inc. Has $1.84 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Edmp Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 2.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 12,737 shares of the company’s stock after selling 377 shares during the period. Johnson & Johnson comprises about 1.7% of Edmp Inc.’s investment portfolio, making the stock its 21st biggest holding. Edmp Inc.’s holdings in Johnson & Johnson were worth $1,842,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in JNJ. Powers Advisory Group LLC grew its position in shares of Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after purchasing an additional 61 shares during the last quarter. Knuff & Co LLC grew its holdings in Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after buying an additional 64 shares during the last quarter. Vertex Planning Partners LLC increased its position in Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after buying an additional 65 shares during the period. Freedom Day Solutions LLC lifted its holdings in shares of Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock worth $1,016,000 after buying an additional 66 shares during the last quarter. Finally, Traphagen Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 0.6% in the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock worth $1,699,000 after acquiring an additional 67 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.7 %

JNJ stock opened at $156.20 on Friday. The business has a fifty day moving average price of $147.73 and a 200 day moving average price of $156.01. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock has a market capitalization of $376.08 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the business posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.